{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:30:28Z","timestamp":1787880628434,"version":"build-2784847793"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004271","name":"Sapienza University of Rome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]},{"name":"I.R.C.C.S. Neuromed"},{"name":"Sant'Andrea Hospital of Rome"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.schres.2019.02.020","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T09:19:30Z","timestamp":1551518370000},"page":"465-466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-8578","authenticated-orcid":false,"given":"Martina","family":"Curto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Lionetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Corigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4557-0931","authenticated-orcid":false,"given":"Anna","family":"Comparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferracuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Simmaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross J.","family":"Baldessarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2019.02.020_bb0005","doi-asserted-by":"crossref","first-page":"17799","DOI":"10.1038\/srep17799","article-title":"Xanthurenic acid activates mGlu2\/3 metabotropic glutamate receptors: a potential trait marker for schizophrenia","volume":"5","author":"Fazio","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.schres.2019.02.020_bb0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2016.06.020","article-title":"Cinnabarinic acid and xanthurenic acid: two kynurenine metabolites that interact with metabotropic glutamate receptors","volume":"112","author":"Fazio","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2019.02.020_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coph.2018.01.010","article-title":"Targeting metabotropic glutamate receptors for the treatment of neuroinflammation","volume":"38","author":"Fazio","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.schres.2019.02.020_bb0020","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2019.02.020_bb0025","first-page":"76","article-title":"Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex","volume":"292","author":"Marek","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2019.02.020_bb0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/A:1022034115078","article-title":"Symptom assessment in schizophrenic prodromal states","volume":"70","author":"Miller","year":"1999","journal-title":"Psychiatric Q."},{"key":"10.1016\/j.schres.2019.02.020_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuron.2013.03.024","article-title":"A mechanistic approach to preventing schizophrenia in at-risk individuals","volume":"10","author":"Moghaddam","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2019.02.020_bb0040","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.schres.2019.02.020_bb0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2019.02.020_bb0050","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrn3257","article-title":"Kynurenines in the mammalian brain: when physiology meets pathology","volume":"13","author":"Schwarcz","year":"2012","journal-title":"Nat. Rev. Neurosci."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419300805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419300805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T10:41:18Z","timestamp":1565174478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996419300805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":10,"alternative-id":["S0920996419300805"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2019.02.020","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2019.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}